Clinical features and outcomes of peripheral T-cell lymphoma, not otherwise specified: A single institution retrospective analysis of 30 cases.

However, this difference did not reach statistical significance, likely due to the limited sample size.

also in 85,168 other papers

In the present study, patients who received chidamide exhibited higher 3-year OS and PFS rates compared with those who did not receive the treatment, with a notable trend toward improved PFS.

also in 2,243 other papers

There was no significant difference between the cyclophosphamide, doxorubicin, vincristine, prednisone and etoposide regimen and the cyclophosphamide, vincristine, doxorubicin and prednisone regimen, whereas combinations with chidamide showed a trend toward an improved PFS.

also in 42,889 other papers